Moonlake Immunotherapeutics (MLTX) Stock Forecast Oct. 30, 2026

This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.

Moonlake Immunotherapeutics is a small-cap company with a market capitalization of $1.07B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.

For MLTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -12.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 0.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)

All daily signals →